Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
This syndrome is characterized by nephrogenic diabetes insipidus, intracerebral calcifications, intellectual deficit, short stature and facial dysmorphism.
Features include: Severe short stature, Nephrogenic diabetes insipidus, Global developmental delay, and Cerebral calcification.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 2 | Global developmental delay, Cerebral calcification |
Biomarker and diagnostic research for nephrogenic diabetes insipidus-intracranial calcification syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for nephrogenic diabetes insipidus-intracranial calcification syndrome.
82 publications have been identified in PubMed for nephrogenic diabetes insipidus-intracranial calcification syndrome. Research spans Review / Meta-Analysis (67%), Basic Science / Preclinical (16%), and Case Report / Case Series (6%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 55 | 67% |
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
1 |
Severe short stature |
Kidneys and urinary system | 1 | Nephrogenic diabetes insipidus |
Hormones | 1 | Nephrogenic diabetes insipidus |
Laboratory research |
13 |
16% |
Patient case studies | 5 | 6% |
Disease patterns and progression | 5 | 6% |
Testing and diagnosis research | 2 | 2% |
Clinical study results | 2 | 2% |
Papazachariou A (2026). [PMID: 41128447](https://pubmed.ncbi.nlm.nih.gov/41128447/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Clinical Trial Publication]
Walther LE (2025). [PMID: 40192781](https://pubmed.ncbi.nlm.nih.gov/40192781/). *HNO*. [Review / Meta-Analysis]
McCarthy FH (2025). [PMID: 40268352](https://pubmed.ncbi.nlm.nih.gov/40268352/). *Cardiol Clin*. [Review / Meta-Analysis]
Dotan A (2025). [PMID: 39931017](https://pubmed.ncbi.nlm.nih.gov/39931017/). *Harefuah*. [Review / Meta-Analysis]
Sakuma H (2025). [PMID: 39143740](https://pubmed.ncbi.nlm.nih.gov/39143740/). *Dev Med Child Neurol*. [Review / Meta-Analysis]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]
Fann Marko R (2025). [PMID: 39987477](https://pubmed.ncbi.nlm.nih.gov/39987477/). *Harefuah*. [Review / Meta-Analysis]
Sánchez-Camacho A (2025). [PMID: 40406130](https://pubmed.ncbi.nlm.nih.gov/40406130/). *Front Immunol*. [Review / Meta-Analysis]
Agrawal R (2025). [PMID: 40200630](https://pubmed.ncbi.nlm.nih.gov/40200630/). *J Assoc Physicians India*. [Review / Meta-Analysis]